Skip Nav Destination
Issues
1 November 2011
-
Cover Image
Cover Image
![issue cover]()
The image displays a section of a human medulloblastoma sample that has been stained with antibodies against the transcription factor FoxM1 (green) and the proliferation marker Ki67 (red). Tumor cell nuclei are visualized by DAPI. Expression of FoxM1 is not restricted to proliferating cells, as revealed by nuclei that are labeled green but lack red staining. For details, see the article by Priller and colleagues on page 6791 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Drug Approval
The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Maria Nieto; Jeanett Borregaard; Jens Ersbøll; George J.A. ten Bosch; Barbara van Zwieten-Boot; Eric Abadie; Jan H.M. Schellens; Francesco Pignatti
CCR Drug Updates
Molecular Pathways
Special Reports
Human Cancer Biology
Disruptive TP53 Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer
Daisuke Sano; Tong-Xin Xie; Thomas J. Ow; Mei Zhao; Curtis R. Pickering; Ge Zhou; Vlad C. Sandulache; David A. Wheeler; Richard A. Gibbs; Carlos Caulin; Jeffrey N. Myers
Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood
Jayasri G. Iyer; Olga K. Afanasiev; Christopher McClurkan; Kelly Paulson; Kotaro Nagase; Lichen Jing; Joshua O. Marshak; Lichun Dong; Joseph Carter; Ivy Lai; Erik Farrar; David Byrd; Denise Galloway; Cassian Yee; David M. Koelle; Paul Nghiem
Cancer Therapy: Preclinical
A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Antitumor Mechanisms against Ovarian Cancer Cells
Shingo Miyamoto; Ryo Iwamoto; Akiko Furuya; Kumiko Takahashi; Yuka Sasaki; Hiroshi Ando; Fusanori Yotsumoto; Tomoko Yoneda; Miki Hamaoka; Hiroshi Yagi; Takuya Murakami; Sayaka Hori; Kenya Shitara; Eisuke Mekada
TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo
Fanny Bouquet; Anupama Pal; Karsten A. Pilones; Sandra Demaria; Byron Hann; Rosemary J. Akhurst; Jim S. Babb; Scott M. Lonning; J. Keith DeWyngaert; Silvia C. Formenti; Mary Helen Barcellos-Hoff
Imaging, Diagnosis, Prognosis
A 5-MicroRNA Signature for Lung Squamous Cell Carcinoma Diagnosis and hsa-miR-31 for Prognosis
Xiaogang Tan; Wenyan Qin; Liang Zhang; Jie Hang; Baozhong Li; Cuiyan Zhang; Junting Wan; Fang Zhou; Kang Shao; Yimin Sun; Jianping Wu; Xun Zhang; Bin Qiu; Ning Li; Susheng Shi; Xiaoli Feng; Shouhua Zhao; Zhen Wang; Xiaohong Zhao; Zhaoli Chen; Keith Mitchelson; Jing Cheng; Yong Guo; Jie He
Cancer Therapy: Clinical
Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer
Nuhad K. Ibrahim; Kemal O. Yariz; Ihor Bondarenko; Alexei Manikhas; Vladimir Semiglazov; Anna Alyasova; Volodymyr Komisarenko; Yaroslav Shparyk; James Lee Murray; David Jones; Shai Senderovich; Albert Chau; Fredrik Erlandsson; Gary Acton; Mark Pegram
A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
Arun Rajan; Ronan J. Kelly; Jane B. Trepel; Yeong Sang Kim; Sylvia V. Alarcon; Shivaani Kummar; Martin Gutierrez; Sonja Crandon; Wadih M. Zein; Lokesh Jain; Baskar Mannargudi; William D. Figg; Brett E. Houk; Michael Shnaidman; Nicoletta Brega; Giuseppe Giaccone
A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies
John W. Moroney; Matthew P. Schlumbrecht; Thorunn Helgason; Robert L. Coleman; Stacy Moulder; Aung Naing; Diane C. Bodurka; Filip Janku; David S. Hong; Razelle Kurzrock
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Paal Fr. Brunsvig; Jon Amund Kyte; Christian Kersten; Stein Sundstrøm; Mona Møller; Marta Nyakas; Gaute L. Hansen; Gustav Gaudernack; Steinar Aamdal
Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group
Judith G. Villablanca; Wendy B. London; Arlene Naranjo; Patrick McGrady; Matthew M. Ames; Joel M. Reid; Renee M. McGovern; Sarah A. Buhrow; Hollie Jackson; Enno Stranzinger; Brenda J. Kitchen; Paul M. Sondel; Marguerite T. Parisi; Barry Shulkin; Gregory A. Yanik; Susan L. Cohn; C. Patrick Reynolds
Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer
Nancy M. Hardy; Miriam E. Mossoba; Seth M. Steinberg; Vicki Fellowes; Xiao-Yi Yan; Frances T. Hakim; Rebecca R. Babb; Daniele Avila; Juan Gea-Banacloche; Claude Sportès; Bruce L. Levine; Carl H. June; Hahn M. Khuu; Ashley E. Carpenter; Michael C. Krumlauf; Andrew J. Dwyer; Ronald E. Gress; Daniel H. Fowler; Michael R. Bishop
Predictive Biomarkers and Personalized Medicine
Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
Matthew P. Goetz; Daniel J. Schaid; D. Lawrence Wickerham; Stephanie Safgren; Taisei Mushiroda; Michiaki Kubo; Anthony Batzler; Joseph P. Costantino; Victor G. Vogel; Soonmyung Paik; Erin E. Carlson; David A. Flockhart; Norman Wolmark; Yusuke Nakamura; Richard M. Weinshilboum; James N. Ingle; Matthew M. Ames
Correction
Advertisement
